Karnofsky Performance Status Calculator — Oncology Functional Assessment

How to Use This Calculator

1. Select the KPS descriptor that best matches the patient's current functional status.
2. KPS score, ECOG equivalent, and clinical implications display instantly.
3. Use the Functional Domains tab to estimate KPS from activity and symptom assessment.
4. Use the Professional tier for diagnosis-specific eligibility and prognosis notes.

Formula

Example

Frequently Asked Questions

• What is the Karnofsky Performance Status (KPS)? ▼
  The Karnofsky Performance Status (KPS) is a standardised scale used in oncology to measure a cancer patient's functional ability and the impact of disease and treatment on their daily activities. Developed by David A. Karnofsky and Joseph H. Burchenal in 1949, it was originally designed to assess the functional effects of nitrogen mustard chemotherapy. The scale ranges from 0 (dead) to 100 (perfectly normal, no evidence of disease) in increments of 10. Higher scores indicate better functional status and ability to perform activities of daily living. The scale is divided into three broad bands: KPS 100–80 (able to carry on normal activity and work; no special care needed), KPS 70–50 (unable to work; able to live at home and care for most personal needs with varying assistance), and KPS 40–10 (unable to care for self; requires equivalent of institutional or hospital care). KPS is used to determine eligibility for clinical trials, guide chemotherapy dosing, assess prognosis, and inform hospice and palliative care referrals. It remains one of the most widely cited oncology assessment tools despite being over 75 years old.
• When is KPS used in oncology practice? ▼
  KPS is used across multiple decision points in oncology. It is a standard eligibility criterion for clinical trials — most trials require KPS ≥70 or ECOG ≤2 for enrolment, ensuring that enrolled patients can tolerate the investigational treatment. In standard clinical practice, KPS ≥70 is the general threshold for proceeding with cytotoxic chemotherapy; patients with KPS below 70 have substantially higher rates of treatment-related toxicity and lower response rates. For hospitalised cancer patients, KPS assessment helps guide the intensity of care, goals-of-care conversations, and discharge planning. In palliative medicine, KPS ≤50 triggers consideration for palliative care consultation, and KPS ≤30 is often used as a threshold for hospice eligibility discussions — at this level, patients are typically spending the majority of their time in bed and median survival is measured in weeks to months. KPS is also used in prognosis models — the Palliative Performance Scale (PPS) is a direct modification of KPS used specifically in hospice settings — and in quality-of-life research as an outcome measure for functional recovery after treatment.
• How does KPS compare to ECOG performance status? ▼
  KPS and ECOG (Eastern Cooperative Oncology Group) Performance Status are the two most widely used functional assessment scales in oncology. ECOG uses a simpler six-point ordinal scale (0–5), where 0 is fully active, 4 is completely disabled, and 5 is dead. ECOG was developed in 1982 by Oken et al. specifically to provide a simpler, more reproducible alternative to KPS for use in clinical trials. The approximate conversions are: ECOG 0 ≈ KPS 100–90, ECOG 1 ≈ KPS 80–70, ECOG 2 ≈ KPS 60–70, ECOG 3 ≈ KPS 40–50, ECOG 4 ≈ KPS 20–30, ECOG 5 = KPS 0. In head-to-head comparisons, inter-rater reliability is similarly modest for both scales. ECOG has become more dominant in clinical trials and most oncology guidelines globally, while KPS is more commonly used in palliative care and hospice settings. KPS allows finer discrimination within functional levels (10-point increments versus 1-point), which may be useful for tracking longitudinal changes. Both scales have significant subjectivity and observer variability; neither captures important dimensions such as cognitive function or emotional wellbeing.
• What is the minimum KPS for chemotherapy eligibility? ▼
  The generally accepted minimum KPS for proceeding with standard cytotoxic chemotherapy is 70, corresponding to a patient who cares for themselves independently but is unable to carry on normal activity or active work. This threshold is supported by multiple retrospective analyses showing that patients with KPS below 70 experience substantially higher rates of severe (grade 3/4) toxicities, treatment delays, dose reductions, and treatment-related mortality. A KPS of 60 describes a patient who requires occasional assistance from others for personal needs; at this level, performance status-adjusted dosing or switch to oral/less-intensive regimens should be considered. For oral targeted therapies and immunotherapy agents, the functional threshold may be more flexible than for intravenous cytotoxics — several immunotherapy trials have enrolled patients with ECOG ≤2 (KPS ≥60). It is important to note that KPS is one factor in the treatment decision — age, comorbidities, organ function, patient preference, and anticipated benefit must all be considered. A single KPS assessment is also limited by its snapshot nature; a patient whose KPS has recently declined rapidly from 80 to 50 due to illness may recover, whereas a patient with a stable chronic KPS of 60 may tolerate treatment differently.
• What KPS scores qualify for hospice eligibility? ▼
  In most hospice and palliative care frameworks, KPS ≤50 is used as a functional trigger for hospice eligibility discussions, and KPS ≤30 is a commonly cited threshold for formal hospice referral. In the United States, Medicare hospice eligibility requires a physician to certify a life expectancy of six months or less if the disease follows its normal course — KPS ≤50 combined with disease-specific decline criteria supports this certification. The Palliative Performance Scale (PPS), a modification of KPS developed specifically for hospice practice, is widely used in Canada and has been validated against survival. A PPS of 20–30% (equivalent to KPS 20–30) is associated with median survival of days to weeks. KPS ≤30 indicates a patient who is severely disabled, hospitalisation is indicated but active treatment is not reasonable, and the patient requires full nursing care. KPS 20 describes a patient who is very sick and in need of active supportive treatment; KPS 10 is moribund with fatal processes progressing rapidly. While KPS provides a useful benchmark, hospice eligibility is a multidimensional clinical judgment incorporating diagnosis trajectory, symptom burden, rate of decline, and patient/family goals.

Related Calculators